|Bid||23.55 x 1000|
|Ask||24.93 x 900|
|Day's Range||24.13 - 24.85|
|52 Week Range||21.05 - 35.63|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||43.33|
Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported second-quarter 2020 financial results.
This question is really less about Moderna's IPO and more about what happened afterward, with the biotech stock tripling in value this year. Pliant Therapeutics (NASDAQ: PLRX) held a successful IPO earlier this month, raising $144 million after originally planning to raise $86 million.
Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced the closing of its initial public offering of 10,350,000 shares of common stock, which includes the exercise in full by the underwriters of their 30-day option to purchase up to an additional 1,350,000 shares of common stock, at a public offering price of $16.00 per share. The aggregate gross proceeds to Pliant from the initial public offering were approximately $165.6 million, before deducting underwriting discounts and commissions and other offering expenses. All of the shares of common stock were offered by Pliant. The shares began trading on The Nasdaq Global Select Market on June 3, 2020, under the ticker symbol "PLRX."